Table 1 PARP inhibitor recommended by 2022 NCCN clinical practice guidelines
PARP inhibitor | Approved year | Indication and Usage | Recommended dose | Associated clinical trial |
|---|---|---|---|---|
Olaparib | 2017 by FDA | platinum sensitive, recurrent ovarian cancer for maintenance treatment | 300Â mg (two 150Â mg tablets) taken orally twice daily | SOLO-2 and Study 19 |
| Â | 2018 by FDA | BRCA1/2- mutated advanced ovarian cancer for first-line maintenance treatment | 300Â mg (two 150Â mg tablets) taken orally twice daily | SOLO-1 |
| Â | 2020 by FDA | platinum sensitive and homologous recombinant deficient positive advanced ovarian cancer for combination with bevacizumab for first-line maintenance treatment | 300Â mg taken orally twice daily | PAOLA-1 |
Niraparib | 2017 by FDA | platinum sensitive and recurrent ovarian cancer for maintenance treatment | based on body weight or platelet count | ENGOT-OV16/NOVA Trial |
| Â | 2019 by FDA | HRD-positive ovarian cancer for maintenance treatment | 300Â mg taken once daily | NCT02354586 |
Rucaparib | 2016 by FDA | BRCA1/2-mutated after receiving at least two lines of prior chemotherapy | not mention | Study 10 and ARIEL2 |
| Â | 2018 by FDA | platinum sensitive, recurrent ovarian cancer for maintenance treatment | 600Â mg (two 300Â mg tablets) taken orally twice daily | ARIEL3 |